Posted by Michael Wonder on 11 Feb 2025
Nivolumab and ipilimumab for the first-line treatment of patients with metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
10 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of nivolumab and ipilimumab in the NHS in England.
For the time being, the combination of nivolumab and ipilimumab is not recommended for the first-line treatment of adults with unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency.
